Valuation Astellas Pharma Inc. OTC Markets

Stocks

ALPMY

US04623U1025

Pharmaceuticals

Market Closed - OTC Markets 01:29:56 15/10/2026 am IST			5-day change	1st Jan Change
14.35 ^USD	-0.28%		+0.77%	+7.98%

08/10	Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer	MT
08/10	Vir Biotechnology, Inc. and Astellas Pharma Inc. Announce FDAFast Track Designation for PSMA-Targeted Pro-XTEN® Dual-Masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer	CI

Company Valuation: Astellas Pharma Inc.

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	35,19,738	33,81,409	29,46,773	25,89,390	45,12,563	40,56,694	-	-
Change	-	-3.93%	-12.85%	-12.13%	74.27%	-10.1%	-	-
Enterprise Value (EV) ¹	32,03,752	30,04,569	26,11,086	32,32,444	47,96,910	39,97,515	35,76,039	32,00,752
Change	-	-6.22%	-13.1%	23.8%	48.4%	-16.66%	-10.54%	-10.49%
P/E	28.5x	34.7x	173x	51x	15.5x	10.3x	11.2x	14.5x
PBR	2.39x	2.24x	1.85x	1.71x	2.47x	1.94x	1.76x	1.67x
PEG	-	-1.8x	-2.1x	0x	0x	0.3x	-1.48x	-0.6x
Capitalization / Revenue	2.72x	2.23x	1.84x	1.35x	2.11x	1.71x	1.84x	2.06x
EV / Revenue	2.47x	1.98x	1.63x	1.69x	2.24x	1.69x	1.62x	1.62x
EV / EBITDA	13.6x	12.6x	14.2x	13.5x	8.31x	5.26x	5.05x	5.31x
EV / EBIT	20.6x	22.6x	102x	78.8x	12.5x	7.85x	7.51x	8.64x
EV / FCF	14.1x	10.3x	-3.88x	20.5x	9.72x	8.64x	6.51x	6.2x
FCF Yield	7.08%	9.7%	-25.8%	4.87%	10.3%	11.6%	15.4%	16.1%
Dividend per Share ²	50	60	70	74	78	80.15	83.08	85.31
Rate of return	2.62%	3.19%	4.26%	5.12%	3.1%	3.54%	3.67%	3.77%
EPS ²	67.08	54.24	9.51	28.35	162.8	219	202.4	155.9
Distribution rate	74.5%	111%	736%	261%	47.9%	36.6%	41%	54.7%
Net sales ¹	12,96,163	15,18,619	16,03,672	19,12,323	21,39,245	23,71,429	22,09,470	19,70,501
EBITDA ¹	2,35,370	2,38,767	1,83,358	2,40,171	5,77,227	7,59,330	7,07,826	6,02,722
EBIT ¹	1,55,686	1,33,029	25,518	41,039	3,82,633	5,08,934	4,76,158	3,70,335
Net income ¹	1,24,086	98,714	17,045	50,747	2,91,535	3,76,912	3,45,056	2,62,291
Net Debt ¹	-3,15,986	-3,76,840	-3,35,687	6,43,054	2,84,347	-59,179	-4,80,654	-8,55,942
Reference price ²	1,911.00	1,883.00	1,643.50	1,446.50	2,519.00	2,262.50	2,262.50	2,262.50
Nbr of stocks (in thousands)	18,41,831	17,95,756	17,92,986	17,90,107	17,91,411	17,93,014	-	-
Announcement Date	27/04/22	27/04/23	25/04/24	25/04/25	27/04/26	-	-	-

¹JPY in Million²JPY

Estimates

P/E, Detailed evolution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	34.58x	12.46x	26.12x	0.57%	1,07700Cr
JOHNSON & JOHNSON	37.53x	6.26x	17.55x	2.1%	61TCr
ABBVIE INC.	36.12x	8.31x	17.13x	2.45%	50TCr
MERCK & CO., INC.	113.84x	6x	25.7x	2.32%	36TCr
ROCHE HOLDING AG	20.01x	4.88x	12.13x	2.7%	35TCr
NOVARTIS AG	20.46x	5.37x	13.21x	2.96%	28TCr
ASTRAZENECA PLC	21.15x	4.27x	12.26x	2.07%	25TCr
AMGEN INC.	27.06x	6.97x	12.48x	2.37%	23TCr
GILEAD SCIENCES, INC.	-44.86x	6.85x	26.64x	2.14%	19TCr
Average	29.54x	6.82x	18.14x	2.19%	42.85TCr
Weighted average by Cap.	35.12x	7.99x	19.65x	1.87%